As more and more oncologic patients are being cured from cancer, problems with long-term c ytostatic cardiologic
complications have triggered and intensive investigation. Cardiotoxicity becomes a specific problem for those who
survived cancer therapy with anthracycline. Heart failure or ventricular arrhythmias may develop from subclinical
myocardial alterations induced by anthracycline therapy. Long-lasting monitoring of cardiac status may help to
identify those patients, whose abnormalities have progressive character and who are at risk of fatal complications
cardiotoxicity, heart failure, ventricular arrhythmias, anthracycline..